HER3 Breast Text Module

CME

Elevating the Science of HER3-Targeted Therapy to Improve Outcomes in Breast Cancer

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: October 13, 2023

Expiration: October 12, 2024

Yuan Yuan
Yuan Yuan, MD, PhD

Activity

Progress
1
Course Completed

In an ongoing phase II trial of patritumab deruxtecan that enrolled patients with previously treated HER2-negative advanced breast cancer, what was the lowest level of HER3 expression associated with antitumor activity?